-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Novaliq announced that the second pivotal phase 3 clinical trial of CyclASol, a topical anti-inflammatory eye drops under investigation, for the treatment of dry eye (DED) has achieved positive results
Dry eye is one of the most common chronic diseases of the eye, affecting the quality of life of millions of people.
Based on Novaliq's proprietary EyeSol technology platform for anhydrous drug delivery, CyclASol is an immunomodulator with local anti-inflammatory effects, containing 0.
This randomized, double-blind, vehicle-controlled, multi-center, pivotal phase 3 clinical trial was carried out in 328 patients with dry eye who did not respond to artificial tears
In terms of safety, the number of adverse events (AE) in the trial was low, usually mild
Reference materials:
[1] Novaliq Announces Positive Topline Results for Second Phase 3 Trial (Essence-2) of CyclASol® in Dry Eye Disease.
[2] Sheppard, JD, et, al.
(The original text has been deleted)